carnitine has been researched along with Anemia, Cooley's in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination of hydroxyurea with l-carnitine or magnesium could be more effective in improving hematologic parameters and cardiac status in patients with beta-thalassemia intermedia than hydroxyurea alone." | 9.14 | Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. ( Amoozgar, H; Behmanesh, F; Borzouee, M; Haghpanah, S; Karimi, M; Mohammadi, F; Samani, SM, 2010) |
| "Carnitine is an essential protein for transportation of long-chain fatty acids to the matrix for beta-oxidation." | 6.78 | Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects. ( Azimi, A; Hadaegh, A; Karimi, M; Mazloom, M; Shahriari, M; Tabei, SM; Zareifar, S, 2013) |
| "L-carnitine is an essential element of intermediary metabolism and also was shown to be effective in maintaining normal red blood cell (RBC) function." | 6.72 | L-carnitine deficiency and red blood cell mechanical impairment in beta-thalassemia major. ( Baskurt, OK; Baykal, A; Isbir, M; Kupesiz, A; Toptas, B; Yalcin, O; Yesilipek, A, 2006) |
| "Bone disease in beta-thalassemia major (betaTM) remains poorly understood." | 5.36 | Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone m ( El-Metwally, TH; Hamed, EA; Kamal, MM; Mohamed, NA, 2010) |
| "In total, 32 patients with beta-thalassemia major were recruited; 16 age- and sex-matched children constituted the control group." | 5.35 | Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. ( El Accaoui, R; El-Beshlawy, A; El-Saidi, S; Makhlouf, A; Mansi, Y; Taher, A; Youssry, I, 2008) |
| "Combination of hydroxyurea with l-carnitine or magnesium could be more effective in improving hematologic parameters and cardiac status in patients with beta-thalassemia intermedia than hydroxyurea alone." | 5.14 | Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. ( Amoozgar, H; Behmanesh, F; Borzouee, M; Haghpanah, S; Karimi, M; Mohammadi, F; Samani, SM, 2010) |
| "Heart failure, fatal arrhythmias, and cardiac dilatation because of anemia are common causes of β-thalassemia major-related deaths." | 2.94 | The Effects of L-Carnitine on Echocardiographic Changes in Patients With β-Thalassemia Major and Intermedia. ( Fattahi, N; Hashemi, SR; Moradveisi, B; Roshani, D; Shahidi, M; Sharifi, P; Vahedi, S, 2020) |
| "Carnitine is an essential protein for transportation of long-chain fatty acids to the matrix for beta-oxidation." | 2.78 | Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects. ( Azimi, A; Hadaegh, A; Karimi, M; Mazloom, M; Shahriari, M; Tabei, SM; Zareifar, S, 2013) |
| "Delayed puberty in beta-thalassemia major is either due to failure of gonads or failure of the whole hypothalamic pituitary gonadal axis." | 2.73 | Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in beta-thalassemic patients. ( Abd El Dayem, SM; Abd El Ghafar, E; Aly, AA; El Beshlawy, A; El Sayed, MH; Farok, M; Mohtar, G, 2008) |
| "L-Carnitine plays an essential role in fatty acid beta-oxidation, a process especially important in the organs that preferentially use fatty acid as a source of energy such as the myocardium and the skeletal muscles." | 2.73 | Effect of L-carnitine on the physical fitness of thalassemic patients. ( Abd El-Sattar, M; El Accaoui, R; El-Beshlawy, A; El-Ghamrawy, M; Gamal El-Deen, MH; Hamdy, M; Shaheen, N; Taher, A; Youssry, I, 2007) |
| "L-carnitine is an essential element of intermediary metabolism and also was shown to be effective in maintaining normal red blood cell (RBC) function." | 2.72 | L-carnitine deficiency and red blood cell mechanical impairment in beta-thalassemia major. ( Baskurt, OK; Baykal, A; Isbir, M; Kupesiz, A; Toptas, B; Yalcin, O; Yesilipek, A, 2006) |
| "Excess iron deposition in patients with beta thalassemia major (BTM) causes excess free radical formation, damages the hypothalamic pituitary testicular axis and production of sperms with DNA defects." | 1.48 | A pilot study on sperm DNA damage in β-thalassemia major: is there a role for antioxidants? ( Ahmed, AY; Arafa, M; De Sanctis, V; Elalfy, MS; Elsedfy, H; Mohamed, NR, 2018) |
| "Mean carnitine was significantly lower (P=0." | 1.36 | L-carnitine in beta thalassemia. ( Jain, A; Kotian, M; Merchant, R; Puri, V; Udani, A, 2010) |
| "Bone disease in beta-thalassemia major (betaTM) remains poorly understood." | 1.36 | Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone m ( El-Metwally, TH; Hamed, EA; Kamal, MM; Mohamed, NA, 2010) |
| "In total, 32 patients with beta-thalassemia major were recruited; 16 age- and sex-matched children constituted the control group." | 1.35 | Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. ( El Accaoui, R; El-Beshlawy, A; El-Saidi, S; Makhlouf, A; Mansi, Y; Taher, A; Youssry, I, 2008) |
| "In patients with homozygous beta thalassemia, the reduction of serum carnitine levels might play an important role in the appearance of muscular dysfunction." | 1.33 | Serum carnitine levels in patients with homozygous beta thalassemia: a possible new role for carnitine? ( Liapi-Adamidou, G; Tsagris, V, 2005) |
| "L-Carnitine seems to be a good modulator of apoptotic processes in thalassemic patients leading to a decreased frequency of programmed erythroblast death and general improvement of the disease condition." | 1.33 | Apoptosis in thalassemia major reduced by a butyrate derivative. ( Aoun, E; El-Beshlawy, A; Gabre, H; Ibrahim, A; Isma'eel, H; Seoud, H; Taher, A; Youssry, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Shahidi, M | 1 |
| Hashemi, SR | 1 |
| Fattahi, N | 1 |
| Roshani, D | 1 |
| Vahedi, S | 1 |
| Sharifi, P | 1 |
| Moradveisi, B | 1 |
| Elsedfy, H | 1 |
| De Sanctis, V | 1 |
| Ahmed, AY | 1 |
| Mohamed, NR | 1 |
| Arafa, M | 1 |
| Elalfy, MS | 1 |
| Tabei, SM | 1 |
| Mazloom, M | 1 |
| Shahriari, M | 1 |
| Zareifar, S | 1 |
| Azimi, A | 1 |
| Hadaegh, A | 1 |
| Karimi, M | 2 |
| El Beshlawy, A | 1 |
| Mohtar, G | 1 |
| Abd El Ghafar, E | 1 |
| Abd El Dayem, SM | 1 |
| El Sayed, MH | 1 |
| Aly, AA | 1 |
| Farok, M | 1 |
| El-Beshlawy, A | 4 |
| Youssry, I | 3 |
| El-Saidi, S | 1 |
| El Accaoui, R | 2 |
| Mansi, Y | 1 |
| Makhlouf, A | 2 |
| Taher, A | 4 |
| Merchant, R | 1 |
| Jain, A | 1 |
| Udani, A | 1 |
| Puri, V | 1 |
| Kotian, M | 1 |
| Mohammadi, F | 1 |
| Behmanesh, F | 1 |
| Samani, SM | 1 |
| Borzouee, M | 1 |
| Amoozgar, H | 1 |
| Haghpanah, S | 1 |
| Hamed, EA | 1 |
| Mohamed, NA | 1 |
| El-Metwally, TH | 1 |
| Kamal, MM | 1 |
| Ragab, L | 1 |
| Fattah, AA | 1 |
| Ibrahim, IY | 1 |
| Hamdy, M | 2 |
| Aoun, E | 2 |
| Hoffbrand, V | 1 |
| Tsagris, V | 1 |
| Liapi-Adamidou, G | 1 |
| Seoud, H | 1 |
| Ibrahim, A | 1 |
| Gabre, H | 1 |
| Isma'eel, H | 1 |
| Toptas, B | 1 |
| Baykal, A | 1 |
| Yesilipek, A | 1 |
| Isbir, M | 1 |
| Kupesiz, A | 1 |
| Yalcin, O | 1 |
| Baskurt, OK | 1 |
| Abd El-Sattar, M | 1 |
| Gamal El-Deen, MH | 1 |
| Shaheen, N | 1 |
| El-Ghamrawy, M | 1 |
| Palmieri, L | 1 |
| Ronca, F | 1 |
| Malengo, S | 1 |
| Bertelli, A | 1 |
| Yeşilipek, MA | 1 |
| Hazar, V | 1 |
| Yegin, O | 1 |
7 trials available for carnitine and Anemia, Cooley's
| Article | Year |
|---|---|
The Effects of L-Carnitine on Echocardiographic Changes in Patients With β-Thalassemia Major and Intermedia.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Carnitine; Case-Control Studies; Child; C | 2020 |
Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects.
Topics: Adolescent; beta-Thalassemia; Carnitine; Child; Child, Preschool; Dietary Supplements; Fatigue; Fema | 2013 |
Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in beta-thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Carnitine; Estrogens; Female; Follow-Up Studies; Hormone Replac | 2008 |
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Urea Nitrogen; Carnitine; Child; Child, Preschool; Creati | 2010 |
Improvement of cardiac function in thalassemia major treated with L-carnitine.
Topics: Adolescent; Adult; Angiography; beta-Thalassemia; Carnitine; Child; Electrocardiography; Female; Hea | 2004 |
L-carnitine deficiency and red blood cell mechanical impairment in beta-thalassemia major.
Topics: Adolescent; beta-Thalassemia; Calcium; Carnitine; Child; Child, Preschool; Dietary Supplements; Eryt | 2006 |
Effect of L-carnitine on the physical fitness of thalassemic patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Carnitine; Child; Comb | 2007 |
8 other studies available for carnitine and Anemia, Cooley's
| Article | Year |
|---|---|
A pilot study on sperm DNA damage in β-thalassemia major: is there a role for antioxidants?
Topics: Acetylcysteine; Adult; Antioxidants; beta-Thalassemia; Carnitine; DNA Damage; DNA Fragmentation; Hum | 2018 |
Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy.
Topics: Administration, Oral; Adolescent; beta-Thalassemia; Carnitine; Case-Control Studies; Child; Child, P | 2008 |
L-carnitine in beta thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Carnitine; Case-Control Studies; Child; Diet | 2010 |
Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone m
Topics: beta-Thalassemia; Blood Transfusion; Bone Density; Carnitine; Case-Control Studies; Chelation Therap | 2010 |
Serum carnitine levels in patients with homozygous beta thalassemia: a possible new role for carnitine?
Topics: Adolescent; Adult; beta-Thalassemia; Carnitine; Case-Control Studies; Child; Child, Preschool; Fatty | 2005 |
Apoptosis in thalassemia major reduced by a butyrate derivative.
Topics: Adolescent; Apoptosis; beta-Thalassemia; Bone Marrow Cells; Carnitine; Child; Child, Preschool; DNA | 2005 |
Protection of beta-thalassaemic erythrocytes from oxidative stress by propionyl carnitine.
Topics: Adult; beta-Thalassemia; Carnitine; Erythrocytes; Female; Humans; Male; Middle Aged; Oxidative Stres | 1994 |
L-Carnitine treatment in beta thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Carnitine; Child; Child, Preschool; Female; Humans; Male | 1998 |